← Leaderboards
Pierluigi Porcu
Ohio State University
$1,519,158
Attributed
$2,887,137
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $745.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,887,137 · 4
By mechanism
R01$1,785,789 · 1
K23$677,565 · 1
R21$354,906 · 1
M01$68,877 · 1
Top collaborators
- Paul M. Lieberman3 shared
- Troy E Messick3 shared
- Henry Keung Wong2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Claire M Kamp Dush$8,201,833
- Tasleem J Padamsee$971,168
- Kimberly Michelle Kelly$655,175
- Lisa Michelle Christian$6,976,440
- Randi Bates$1,508,819
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchMalignant NeoplasmsResponsePatternNeoplastic CellPatient PopulationLymphomaEpstein-Barr Virus-Related LymphomaGrantLinkMonoclonal AntibodyCellsClinical Trial Phase IDoseClinical TrialsDrug KineticsEnrollmentBiologicalGene ExpressionGenesIn VivoLeadAffectFunding
Grant awards (11)
EBNA1 Inhibitor for Treatment of EBV-positive DLBCL$534,316
R01 · FY2025 · CA
EBNA1 Inhibitor for Treatment of EBV-positive DLBCL$505,631
R01 · FY2024 · CA
EBNA1 Inhibitor for Treatment of EBV-positive DLBCL$745,842
R01 · FY2023 · CA
Novel Biomarkers in Cutaneous T Cell Lymphoma$155,893
R21 · FY2013 · CA
Novel Biomarkers in Cutaneous T Cell Lymphoma$199,013
R21 · FY2012 · CA
Combined Cytokine-Monoclonal Antibody Therapy in Lymphoma$135,513
K23 · FY2007 · CA · contact PI
Combined Cytokine-Monoclonal Antibody Therapy - Lymphoma$135,513
K23 · FY2006 · CA · contact PI
Combined Cytokine-Monoclonal Antibody Therapy - Lymphoma$135,513
K23 · FY2005 · CA
Combined Cytokine-Monoclonal Antibody Therapy - Lymphoma$135,513
K23 · FY2004 · CA
Phase I Study of Thrice Weekly Hu1D10 in CLL/ALL Patient$68,877
M01 · FY2004 · RR
Combined Cytokine-Monoclonal Antibody Therapy - Lymphoma$135,513
K23 · FY2003 · CA